<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186378</url>
  </required_header>
  <id_info>
    <org_study_id>VP-102-103</org_study_id>
    <nct_id>NCT03186378</nct_id>
  </id_info>
  <brief_title>Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.</brief_title>
  <official_title>A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verrica Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paidion Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Database Integrations, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instat services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Verrica Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the presence or absence of systemic&#xD;
      cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming&#xD;
      solution [0.7% (w/v) cantharidin] (VP-102) when applied to molluscum contagiosum (molluscum)&#xD;
      lesions on pediatric subjects 2 years old and older. Treatment will continue over the course&#xD;
      of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and&#xD;
      impact on quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of&#xD;
      VP-102 Topical Film Forming Solution [0.7% (w/v) cantharidin] in subjects 2 years and older&#xD;
      with Molluscum Contagiosum. Up to 40 subjects will be enrolled in the study with the goal of&#xD;
      16 meeting criteria for, and completing all scheduled blood draws outlined in the exposure&#xD;
      portion of the trial. Subjects that do not have enough molluscum lesions to participate in&#xD;
      the exposure study but do meet all other criteria to participate in the study will be&#xD;
      enrolled in the standard treatment group. No more than 16 subjects will complete exposure&#xD;
      group activities; up to 16 subjects will be enrolled in the standard treatment group. The&#xD;
      additional 8 subjects may be used for replacement patients. At least 3 patients in the&#xD;
      exposure group will be from 2-5 years of age. All subjects will receive VP-102 containing&#xD;
      0.7% cantharidin to molluscum lesions every 21 days for a maximum of 4 sessions or until&#xD;
      complete clearance.&#xD;
&#xD;
      In the exposure group, blood samples for systemic exposure evaluation will be collected on&#xD;
      Day 1, prior to the drug application, and 2 (± 30 minutes), 6 (± 1 hour) and 24 (±3 hours)&#xD;
      hours post-application. A dermatological examination will be performed by a qualified&#xD;
      investigator quantifying molluscum lesion counts at every study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Efficacy - Complete Clearance</measure>
    <time_frame>Baseline through EOS Day 84</time_frame>
    <description>Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.</measure>
    <time_frame>Baseline to EOS Day 84</time_frame>
    <description>Summaries of &gt;=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.</measure>
    <time_frame>Baseline to EOS Day 84</time_frame>
    <description>Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.</measure>
    <time_frame>Baseline to EOS Day 84</time_frame>
    <description>Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment</measure>
    <time_frame>Baseline to EOS Day 84</time_frame>
    <description>Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score&#xD;
The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response:&#xD;
3: Very much (or Prevented School, Question 7 only)&#xD;
2: Quite a lot&#xD;
1: Only a little&#xD;
0: Not at all</description>
  </other_outcome>
  <other_outcome>
    <measure>Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.</measure>
    <time_frame>Baseline to EOS Day 84</time_frame>
    <description>Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>Exposure Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VP-102 with applicator</intervention_name>
    <description>Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
    <arm_group_label>Exposure Group</arm_group_label>
    <arm_group_label>Standard Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be healthy subjects ages 2 years and older.&#xD;
&#xD;
          2. Patients with 1-20 lesions may be enrolled and treated in the standard treatment group&#xD;
             but are not eligible for the exposure study.&#xD;
&#xD;
          3. Patients with 21 or more lesions may only be enrolled in the exposure group. Subjects&#xD;
             participating in the Exposure group must have at least 21 lesions treated at Day 1 to&#xD;
             qualify.&#xD;
&#xD;
          4. Be otherwise medically healthy with no clinically significant medical history as&#xD;
             determined by the investigator. Patients exhibiting active Atopic Dermatitis may be&#xD;
             enrolled.&#xD;
&#xD;
          5. Refrain from application of all topical agents including alcohol-based sanitary&#xD;
             products and sunscreens for a minimum of 4 hours before Study drug application.&#xD;
             Topical agents including alcohol-based sanitary products and sunscreens may be used&#xD;
             after application of the study drug so long as they are not applied to or near treated&#xD;
             skin.&#xD;
&#xD;
          6. Refrain from swimming, bathing or prolonged immersion in water until the Study drug is&#xD;
             removed.&#xD;
&#xD;
          7. Have the ability or have a guardian able to follow study instructions and be likely to&#xD;
             complete all study requirements.&#xD;
&#xD;
          8. Provide assent in a manner approved by the institutional review board (IRB) and have a&#xD;
             parent/guardian provide written informed consent as evidenced by signature on IRB&#xD;
             approved assent/consent forms.&#xD;
&#xD;
          9. Provide written authorization for use and disclosure of protected health information.&#xD;
&#xD;
         10. Agree to allow photographs of all selected lesions to be taken and/or send photos via&#xD;
             text or email to the study team for assessment at 24 hours post treatment. Photos may&#xD;
             be used as part of the study data and/or marketing package. (Photographs will be&#xD;
             de-identified to those outside the research team. Effort will be made to ensure that&#xD;
             no photos with identifiable features are obtained).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are unable to cooperate with the requirements or visits of the study, as determined by&#xD;
             the investigator.&#xD;
&#xD;
          2. Have molluscum venereum (sexually transmitted molluscum).&#xD;
&#xD;
          3. Have active molluscum eczema.&#xD;
&#xD;
          4. Are systemically immunosuppressed or are receiving treatments such as chemotherapy or&#xD;
             other non-topical immunosuppressive agents.&#xD;
&#xD;
          5. Have had any previous treatment of molluscum in the past 14 days including the use of&#xD;
             cantharidin, antivirals, retinoids, curettage or freezing of lesions. Additional&#xD;
             treatments for molluscum should not be implemented during the course of the study.&#xD;
&#xD;
          6. Have history of illness or any dermatologic disorder, which, in the opinion of the&#xD;
             investigator will interfere with accurate counting of lesions or increase the risk of&#xD;
             adverse events.&#xD;
&#xD;
          7. History or presence of clinically significant medical, psychiatric, or emotional&#xD;
             condition or abnormality that in the opinion of the investigator would compromise the&#xD;
             safety of the subject or the quality of the data.&#xD;
&#xD;
          8. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the&#xD;
             Study drug or related compounds, or drug product excipients.&#xD;
&#xD;
          9. Have a condition or situation that may interfere significantly with the subject's&#xD;
             participation in the study (e.g., patients who required hospitalization in the 2&#xD;
             months prior to screening for an acute or chronic condition including alcohol or drug&#xD;
             abuse), at the discretion of the investigator.&#xD;
&#xD;
         10. Have received another investigational product within 14 days prior to the first&#xD;
             application of the Study drug.&#xD;
&#xD;
         11. Have been treated within 14 days with a product that contains the active ingredient in&#xD;
             VP-102 (topical or homeopathic preparations) for any reason prior to screening.&#xD;
&#xD;
         12. Are sexually active or may become sexually active and are unwilling to practice&#xD;
             responsible birth control methods. Females that have reached menarche, must have a&#xD;
             negative urine pregnancy test at screening and each visit prior to treatment with&#xD;
             study medication.&#xD;
&#xD;
         13. Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Goldenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Verrica Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Children's Health</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <results_first_submitted>June 22, 2021</results_first_submitted>
  <results_first_submitted_qc>July 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <disposition_first_submitted>July 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 15, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 9, 2021</disposition_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03186378/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03186378/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exposure Group</title>
          <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
        <group group_id="P2">
          <title>Standard Group</title>
          <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population</population>
      <group_list>
        <group group_id="B1">
          <title>Exposure Group</title>
          <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
        <group group_id="B2">
          <title>Standard Group</title>
          <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="3.45"/>
                    <measurement group_id="B2" value="6.8" spread="3.15"/>
                    <measurement group_id="B3" value="6.7" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Number of Molluscum Lesions</title>
          <units>molluscum lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="25.69"/>
                    <measurement group_id="B2" value="11.6" spread="6.33"/>
                    <measurement group_id="B3" value="30.0" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.</title>
        <description>The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102.</title>
          <description>The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Efficacy - Complete Clearance</title>
        <description>Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).</description>
        <time_frame>Baseline through EOS Day 84</time_frame>
        <population>Complete Clearance of Molluscum Lesions - Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Efficacy - Complete Clearance</title>
          <description>Proportion of subjects exhibiting complete clearance of all treated molluscum lesions (baseline and new) on or before Week 12 (EOS).</description>
          <population>Complete Clearance of Molluscum Lesions - Completer Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Clearance Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance EOS Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.</title>
        <description>Summaries of &gt;=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.</description>
        <time_frame>Baseline to EOS Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit.</title>
          <description>Summaries of &gt;=90% clearance by visit include clearance at that visit or any earlier visit (cumulative) baseline and ew at the EOS visit.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=90% Clearance Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=90% Clearance Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=90% Clearance Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=90% Clearance Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.</title>
        <description>Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.</description>
        <time_frame>Baseline to EOS Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction of Treated Molluscum Lesions From Baseline at the EOS Visit.</title>
          <description>Percent reduction of treated molluscum lesions from Baseline Visit at the EOS visit.</description>
          <population>ITT Population</population>
          <units>percentage change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.8" spread="21.25"/>
                    <measurement group_id="O2" value="-93.0" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.</title>
        <description>Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit</description>
        <time_frame>Baseline to EOS Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Number of Treated Molluscum Lesions at the EOS Visit.</title>
          <description>Molluscum Lesions- Change from Baseline visit in the number of treated molluscum lesions at the EOS Day 84 visit</description>
          <population>ITT Population</population>
          <units>change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.3" spread="21.98"/>
                    <measurement group_id="O2" value="-10.7" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment</title>
        <description>Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score&#xD;
The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response:&#xD;
3: Very much (or Prevented School, Question 7 only)&#xD;
2: Quite a lot&#xD;
1: Only a little&#xD;
0: Not at all</description>
        <time_frame>Baseline to EOS Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life and Impact of Skin Disease as Measured by CDLQI Assessment</title>
          <description>Change from Baseline in quality of life and impact of skin disease as measured by CDLQI assessment, Children's Dermatology Life Quality Index (CDLQI)- Composite Score&#xD;
The CDLQI was a 10-item questionnaire completed by subject/parent to assess skin condition over the previous week. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response:&#xD;
3: Very much (or Prevented School, Question 7 only)&#xD;
2: Quite a lot&#xD;
1: Only a little&#xD;
0: Not at all</description>
          <population>ITT Population</population>
          <units>units on a scale change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="2.801"/>
                    <measurement group_id="O2" value="2.44" spread="4.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.</title>
        <description>Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.</description>
        <time_frame>Baseline to EOS Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Exposure Group</title>
            <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
          <group group_id="O2">
            <title>Standard Group</title>
            <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
          </group>
        </group_list>
        <measure>
          <title>Spread to Siblings as Measured by Any New Occurrence of Molluscum in Siblings of the Subject.</title>
          <description>Spread of molluscum to siblings as measured by any new occurrence of molluscum in siblings of the subject.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to EOS Day 84</time_frame>
      <desc>Adverse events summaries will only consider (TEAEs). TEAEs are defined as those AEs that occurred after dosing and those existing AEs that worsened during the study. If it cannot be determined whether the AE is treatment emergent due to an incomplete onset date, the AE will be considered to be treatment emergent.</desc>
      <group_list>
        <group group_id="E1">
          <title>Exposure Group</title>
          <description>This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
        <group group_id="E2">
          <title>Standard Group</title>
          <description>This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.&#xD;
VP-102 with applicator: Subjects will receive treatment to their molluscum contagiosum with VP-102.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Cutler, VP, Medical Affairs</name_or_title>
      <organization>Verrica Pharmaceuticals</organization>
      <phone>484-773-0898</phone>
      <email>scutler@verrica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

